Moclobemide

This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H17ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PJ0Y7AZB63, chemically known as benzamide, 4-chloro-n-(2-(4-morpholinyl)ethyl)- but generally known as moclobemide, which bears US NIH Compound Identifier 4235. European Medicines Agency schedules Moclobemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09024MIG. The term MOCLOBEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules moclobemide in its Anatomical Therapeutic Chemical (ATC) Classification. MOCLOBEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moclobemide under HS 29349990 and SITC 51579. As of Q4 2014, MOCLOBEMIDE remains the US FDA Preferred Term for this commodity. Moclobemide bears US NLM identifiers UMLS ID C0066673 and NCI Concept Code C87772. SMILES: Clc1ccc(C(=O)NCCN2CCOCC2)cc1.